Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.40 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11037307 | 1.00 | ITGB3 (0.40) | ITGB3ITGA2BCTSKCTSSCA1 | |
| SCHEMBL3851080 | 1.00 | ITGB3 (0.40) | ITGB3ITGA2BCTSKCTSSCA1 | |
| SCHEMBL27535461 | 0.95 | CTSK (0.41) | ITGB3ITGA2BCTSKCTSSCA1 | |
| SCHEMBL8183200 | 0.87 | CTSK (0.45) | ITGB3ITGA2BCTSKCTSSCA1 | |
| SCHEMBL3818708 | 0.84 | MEN1 (0.55) | CTSKCTSSCA1CA2MEN1 | |
| SCHEMBL3498470 | 0.84 | MEN1 (0.55) | CTSKCTSSCA1CA2MEN1 | |
| SCHEMBL9515168 | 0.81 | CTSK (0.52) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL19974088 | 0.80 | CA1 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2427380 | 0.80 | CA1 (0.41) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL11009929 | 0.80 | CTSS (0.45) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA, INC. (US) | 2019-04-30 | — | — | US | claimed |
| CN-105017481-B | Cross-linked polyvinylamine, polyallylamine as bile acid sequestrant and aziridine | 瑞立普萨公司 | 2018-10-02 | — | — | CN | claimed |
| CN-107266681-A | Amine polymer as bile acid sequestrant | 瑞立普萨公司 | 2017-10-20 | — | — | CN | claimed |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. | 2017-09-14 | — | — | US | claimed |
| EP-2998329-A2 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2016-03-23 | — | — | EP | claimed |
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2016-02-25 | — | — | US | claimed |
| CN-105017481-A | Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA INC | 2015-11-04 | — | — | CN | claimed |
| EP-2539380-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| EP-2539389-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| WO-2011106542-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| WO-2011106548-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| EP-0214570-A2 | N-alkylated tripeptides, process for their preparation, medicaments containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-03-18 | — | — | EP | claimed |
| EP-0030920-B1 | ACYL PEPTIDES AND PHARMACEUTICAL PREPARATIONS THEREOF, AS WELL AS THEIR MANUFACTURE AND USE | CIBA-GEIGY AG (CH) | 1984-02-15 | — | — | EP | claimed |
| EP-0030920-A2 | Acyl peptides and pharmaceutical preparations thereof, as well as their manufacture and use | CIBA-GEIGY AG (CH) | 1981-06-24 | — | — | EP | claimed |
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2539389-B1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2017-12-20 | — | — | EP | disclosed |
| CN-107266681-A | Amine polymer as bile acid sequestrant | 瑞立普萨公司 | 2017-10-20 | — | — | CN | disclosed |
| EP-2539380-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011106542-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106548-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, GPBAR1 | ITGB3 3105/4885ITGA2B 4148/4885CTSK 4156/4885 |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, SLC10A1 | ITGB3 2895/4885ITGA2B 4153/4885CTSK 3267/4885 |
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | NR1H4, SLC10A2, GPBAR1 | ITGB3 3105/4885ITGA2B 4148/4885CTSK 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.